Chad D. Galderisi

MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR.

MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR.

MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR.

MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR.

MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR.

MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR.

MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR.

MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR.

MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR.